Illumina has appointed Daniel Bradbury to its board of directors. Bradbury is currently chief operating officer of Amylin Pharmaceuticals and a member of the board of directors of Peninsula Pharmaceuticals. He holds a pharmacy degree from Nottingham University and a diploma in management studies from Harrow and Ealing Colleges of Higher Education. He is also a member of the Royal Pharmaceutical Society of Great Britain.
Ciphergen Biosystems has promoted Martin Verhoef to president of the Ciphergen Biosystems Division, a new business unit of Ciphergen Biosytems. He also becomes executive vice president of Ciphergen Biosystems.
In his new position, Verhoef will lead the company’s Research Products Group and Ciphergen’s Bioprocess Products Group. He will report to William Rich, president and CEO of Ciphergen.
Verhoef joined Ciphergen in April 2000, and most recently was senior vice president of sales, marketing, and operations. Prior to joining Ciphergen, he was with Hewlett-Packard/Agilent Technologies, where he held positions in their Germany-based liquid chromatography division and then in their California-based DNA microarray business. The company also appointed Gail Page as president of its newly formed Diagnostics Division, and made her an executive vice president of Ciphergen Biosystems. In her new position, Page will seek to develop and commercialize protein molecular diagnostics, based on the ProteinChip platform. She also will report to Rich.
Page comes to Ciphergen from Luminex, where she was executive vice president and chief operating officer. She received her medical technology degree in 1976 from the University of Florida in combination with an AS degree in cardiopulmonary technology.
Strategic Diagnostics has eliminated the chief operating officer position. As a result, COO Art Koch has left the company. Koch joined the company in 1997 as its CFO, and became COO in October 1998.
Qiagen has hired Noel Doheny as vice president of solutions for molecular diagnostics, a newly created position. He will be based in the company’s Maryland headquarters and will report to CEO Peer Schatz.
Doheny joins Qiagen from ThermoBioStar, where he had been president and, most recently, director of strategic planning and business development. At Qiagen, Doheny will be responsible for the company’s strategy and market-development activities related to nucleic acid sample preparation for clinical diagnostics.